Hypertension:
- Alnylam (ZENITH): Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease (ZENITH)
PI: Henderson; Coordinator: Sherry x3009
https://clinicaltrials.gov/study/NCT07181109
Polycystic Kidney Disease:
- AbbVie: A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of ABBV-CLS-628 in Adult Subjects With Autosomal Dominant Polycystic Kidney Disease (ADPKD)
PI: Bellovich; Coordinator: Rosemarie x1251
https://clinicaltrials.gov/study/NCT06902558
- Novartis: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study in Patients with
Autosomal Dominant Polycystic Kidney Disease to Evaluate the Efficacy and Safety of Farabursen
PI: Bellovich; Coordinator: Rosemarie.
Glomerular:
- ADARx: A Phase 2 Study to Assess ADX-038 in Participants with Complement-Mediated Kidney Disease.
PI: Topf; Coordinator: Liz
https://clinicaltrials.gov/study/NCT06989359
- Walden Biosciences: Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of WAL0921 in Patients with Glomerular Kidney Diseases and Proteinuria
PI: Topf; Liz
https://clinicaltrials.gov/study/NCT06466135
- Biohaven: An Open-Label Biomarker Study of BHV-1400 in IgA Nephropathy
PI: Topf; Liz
https://clinicaltrials.gov/study/NCT07054684
- Otsuka: IgAN – A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of Sibeprenlimab Administered Subcutaneously in Subjects with Immunoglobulin A Nephropathy.
PI: Topf; Coordinator: Rosemarie
https://clinicaltrials.gov/study/NCT05248646
https://clinicaltrials.gov/study/NCT05248659
- Alpine Sciences: RANIER A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Povetacicept in Adults with Immunoglobulin A Nephropathy.
PI: Topf; Coordinator: Liz
https://clinicaltrials.gov/study/NCT06564142
- BI: BI434-0017 A multicentre, randomised, double-blind, parallel group, placebo-controlled trial
to assess the effects of oral TRPC6 inhibitor BI 764198 taken over a 104 week treatment period in adult and adolescent participants with primary focal segmental glomerulosclerosis (pFSGS) or genetic FSGS related to TRPC6 gene variants.
PI: Bellovich; Coordinator: Liz
https://clinicaltrials.gov/study/NCT07220083
- BI: 1434-0027 PODOMOUNT: Basket, a Phase II, multicentre, randomised, 2-arm parallel-group, double-blind, placebo-controlled basket trial to assess safety, tolerability, PK, and efficacy of BI 764198 in four proteinuric kidney diseases
PI: Dimitrijevic; Coordinator: Liz
https://clinicaltrials.gov/study/NCT07355296
Chronic Kidney Disease:
- EASI-Kidney: Studies of Heart & Kidney Protection with BI 690517: A multicenter international randomized double-blind placebo-controlled clinical trial of the aldosterone synthase inhibitor BI 690517 in combination with empagliflozin in patients with chronic kidney disease.
PI: Provenzano; Coordinator: Sherry x3009
https://clinicaltrials.gov/study/NCT06531824
- ProKidney: A Phase 3 Randomized Controlled Study of Re Autologous Cell Therapy (REACT) in Subjects with Type 2 Diabetes and CKD.
PI: Bellovich; Coordinator: Sherry x3009
https://clinicaltrials.gov/study/NCT05099770
Renal Amyloidosis:
- FLORAL: DapagliFLOzin in Renal AL Amyloidosis (FLORAL) This study aims to study the safety and efficacy of dapagliflozin, a sodiumglucose cotransporter-2 inhibitor (SGLT2i) in patients with renal amyloid light-chain (AL) amyloidosis in a decentralized manner.
Sub-I: Topf; Coordinator: Lori x1224
https://clinicaltrials.gov/study/NCT06420167
- EXPAND: Expanding and Promoting Alternative Care and Knowledge in Decision Making: The ExPAND Study (Improving Shared Decision-Making and Access to Non-Dialytic Treatment for People with Kidney Disease (Patient Centered Outcome Research Institute): Patient choice in Kidney Failure Project. West Virginia University.
PI: Bellovich; Liz x1211
End Stage Renal Disease on Dialysis:
- CSL Behring: Phase 3: (continuation of Phase 2b Multicenter, Randomized, Double-blind, Placebo-controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects with End Stage Kidney Disease Undergoing Dialysis.
PI: Topf; Coordinator: Rosemarie x1251
https://clinicaltrials.gov/study/NCT05485961
- AP306-HP-202: A Phase 2b, Randomized, Double-Blinded, Placebo-Controlled, Multicenter Study to Evaluate the Safety, Tolerability, and Serum Phosphate Lowering Effect of Fixed Dose AP306 in Participants with Hyperphosphatemia Receiving Maintenance Hemodialysis
PI: Topf; Coordinator: Rosemarie
https://clinicaltrials.gov/study/NCT06712654
APOL1-Mediated Kidney Disease:
- MAZE Therapeutics: An Open-Label Phase 2 Study to Evaluate the Safety, Tolerability, and Effect on Albuminuria of MZE829 in Adults with Proteinuric Chronic Kidney Disease and the APOL1 High Risk Genotype
PI: Provenzano; Coordinator: Rosemarie x1251
https://clinicaltrials.gov/study/NCT06830629
- AstraZeneca: Phase 2b Multicentre, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Dose-Ranging Study to Assess the Efficacy, Safety, and Tolerability of AZD2373 in Participants With APOL1-Mediated Kidney Disease (APPRECIATE)
PI: Provenzano; Coordinator: Rosemarie x1251